Citigroup Inc Oncternal Therapeutics, Inc. Transaction History

Citigroup Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	SELL	$0.7 - $1.56 $130 - $291	-187 Reduced 9.82%	1,718 $2,000
Q1 2022 May 12, 2022	SELL	$1.37 - $2.43 $12,841 - $22,776	-9,373 Reduced 83.11%	1,905 $3,000
Q4 2021 Feb 10, 2022	BUY	$2.27 - $4.39 $13,924 - $26,928	6,134 Added 119.25%	11,278 $26,000
Q3 2021 Nov 10, 2021	BUY	$3.37 - $4.76 $17,335 - $24,485	5,144 New	5,144 $21,000

362K

Ticker ONCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,517,200
Market Cap $29.4M
Description
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a smal...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.